Key Takeaways
- • QIAGEN agreed on October 21, 2026 to support a voluntary all-cash takeover offer from EQT Private Equity valued at approximately €10.8 billion ($12.1 billion), including roughly $1.1 billion in net debt.
- • The offer of €46.50 per share represents a 40.3% premium to QIAGEN's July 8, 2026 closing price of €33.15 and a 46.9% premium to its three-month VWAP of €31.66.
- • Crown NL Bidco B.V., indirectly controlled by EQT XI, will make the offer, with Abu Dhabi Investment Authority (via Luxinva S.A.) and CPP Investments participating.
- • The deal requires at least 50% plus one share tendered, an Extraordinary General Meeting vote, merger control and foreign investment clearances, and BaFin approval of the offer document; closing is expected in mid-2027.
- • EQT has committed equity and debt financing and the offer carries no financing condition; completion would delist QIAGEN from the NYSE and Frankfurt Stock Exchange.
Summary
QIAGEN, a molecular diagnostics and life sciences technology company with its North American headquarters in Germantown, Maryland, announced on October 21, 2026 that it supports a voluntary all-cash public takeover offer from EQT Private Equity. The proposed transaction values the company at approximately €10.8 billion ($12.1 billion), including roughly $1.1 billion in net debt, and would take the publicly traded company private if completed. Stephen H. Rusckowski, Chairman of QIAGEN's Supervisory Board, said the transaction "offers shareholders compelling value while positioning QIAGEN for its next phase of development under private ownership."
Under the agreement, Crown NL Bidco B.V., a holding company indirectly controlled by EQT XI, will offer shareholders €46.50 in cash per share. The price represents a 40.3% premium over QIAGEN's July 8, 2026 closing price of €33.15, the last trading day before reports emerged regarding private equity interest, and a 46.9% premium over the three-month volume-weighted average share price of €31.66. QIAGEN's Supervisory and Managing Boards unanimously approved the business combination agreement after reviewing strategic alternatives, including discussions with financial and strategic parties. The acquisition includes participation from Abu Dhabi Investment Authority through its subsidiary Luxinva S.A. and from CPP Investments through a subsidiary.
The transaction remains subject to several conditions. At least 50% of outstanding shares plus one additional share must be tendered, shareholders must consider resolutions at an Extraordinary General Meeting, and the deal requires merger control and foreign investment approvals. The offer document must also receive clearance from Germany's Federal Financial Supervisory Authority before the acceptance period begins. The companies expect to complete the takeover in mid-2027. EQT has secured committed equity and debt financing for the offer consideration and transaction costs, and the offer is not subject to a financing condition. If completed, the deal would end QIAGEN's listings on the New York Stock Exchange and Frankfurt Stock Exchange. Until then, QIAGEN will continue operating under its existing management.
For Maryland's life sciences sector, the deal connects QIAGEN's Germantown headquarters to the BioHealth Capital Region. The company maintains manufacturing, warehousing, distribution, and administrative operations in Germantown, plus a facility in Frederick supporting development, manufacturing, and other services. The companies have not disclosed specific new investments, facility expansions, or workforce changes for the region.
QIAGEN N.V., a Netherlands-based company, provides technologies for extracting, processing, and analyzing DNA, RNA, and proteins, including assay technologies, laboratory automation, and bioinformatics tools. It serves more than 500,000 customers worldwide and employed approximately 5,400 people across more than 35 locations as of September 30, 2026. EQT, headquartered in Stockholm, reported €354 billion in total assets under management and €195 billion in fee-generating assets as of September 30, 2026.
Under the agreement, Crown NL Bidco B.V., a holding company indirectly controlled by EQT XI, will offer shareholders €46.50 in cash per share. The price represents a 40.3% premium over QIAGEN's July 8, 2026 closing price of €33.15, the last trading day before reports emerged regarding private equity interest, and a 46.9% premium over the three-month volume-weighted average share price of €31.66. QIAGEN's Supervisory and Managing Boards unanimously approved the business combination agreement after reviewing strategic alternatives, including discussions with financial and strategic parties. The acquisition includes participation from Abu Dhabi Investment Authority through its subsidiary Luxinva S.A. and from CPP Investments through a subsidiary.
The transaction remains subject to several conditions. At least 50% of outstanding shares plus one additional share must be tendered, shareholders must consider resolutions at an Extraordinary General Meeting, and the deal requires merger control and foreign investment approvals. The offer document must also receive clearance from Germany's Federal Financial Supervisory Authority before the acceptance period begins. The companies expect to complete the takeover in mid-2027. EQT has secured committed equity and debt financing for the offer consideration and transaction costs, and the offer is not subject to a financing condition. If completed, the deal would end QIAGEN's listings on the New York Stock Exchange and Frankfurt Stock Exchange. Until then, QIAGEN will continue operating under its existing management.
For Maryland's life sciences sector, the deal connects QIAGEN's Germantown headquarters to the BioHealth Capital Region. The company maintains manufacturing, warehousing, distribution, and administrative operations in Germantown, plus a facility in Frederick supporting development, manufacturing, and other services. The companies have not disclosed specific new investments, facility expansions, or workforce changes for the region.
QIAGEN N.V., a Netherlands-based company, provides technologies for extracting, processing, and analyzing DNA, RNA, and proteins, including assay technologies, laboratory automation, and bioinformatics tools. It serves more than 500,000 customers worldwide and employed approximately 5,400 people across more than 35 locations as of September 30, 2026. EQT, headquartered in Stockholm, reported €354 billion in total assets under management and €195 billion in fee-generating assets as of September 30, 2026.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.